- Home
- OI vs CNTA Comparison
OI vs CNTA Comparison
Compare OI & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OI
- CNTA
- Stock Information
- Founded
- OI 1903
- CNTA 2020
- Country
- OI United States
- CNTA United Kingdom
- Employees
- OI N/A
- CNTA N/A
- Industry
- OI Containers/Packaging
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- OI Consumer Discretionary
- CNTA Health Care
- Exchange
- OI Nasdaq
- CNTA Nasdaq
- Market Cap
- OI 1.6B
- CNTA 2.3B
- IPO Year
- OI N/A
- CNTA 2021
- Fundamental
- Price
- OI $10.92
- CNTA $17.03
- Analyst Decision
- OI Buy
- CNTA Strong Buy
- Analyst Count
- OI 8
- CNTA 7
- Target Price
- OI $16.25
- CNTA $23.71
- AVG Volume (30 Days)
- OI 1.5M
- CNTA 591.5K
- Earning Date
- OI 02-04-2025
- CNTA 11-12-2024
- Dividend Yield
- OI N/A
- CNTA N/A
- EPS Growth
- OI N/A
- CNTA N/A
- EPS
- OI N/A
- CNTA N/A
- Revenue
- OI $6,643,000,000.00
- CNTA $6,853,000.00
- Revenue This Year
- OI N/A
- CNTA N/A
- Revenue Next Year
- OI N/A
- CNTA N/A
- P/E Ratio
- OI N/A
- CNTA N/A
- Revenue Growth
- OI N/A
- CNTA N/A
- 52 Week Low
- OI $9.85
- CNTA $6.65
- 52 Week High
- OI $17.58
- CNTA $18.97
- Technical
- Relative Strength Index (RSI)
- OI 48.73
- CNTA 47.86
- Support Level
- OI $10.03
- CNTA $15.45
- Resistance Level
- OI $10.39
- CNTA $17.00
- Average True Range (ATR)
- OI 0.44
- CNTA 1.10
- MACD
- OI 0.07
- CNTA -0.10
- Stochastic Oscillator
- OI 63.30
- CNTA 47.00
About OI O-I Glass Inc.
O-I Glass is the world's largest manufacturer of glass bottles; 70% of its revenue comes from outside the United States. O-I has a leading position in key markets such as Europe, North America, and Brazil. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food. O-I is looking to maintain or expand its dominant positions in Europe, North America, and South America.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.